Fresh off its approval from the US Food and Drug Administration, Axsome Therapeutics’ migraine drug Symbravo (meloxicam and rizatriptan) stands to potentially strengthen its position in a crowded marketplace, with data showing it can treat patients who have not responded well to the CGRP inhibitors that currently dominate that market.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?